anxiety disorders

Psychedelics biotech Silo Pharma Inc. (NASDAQ: SILO) and Columbia University are developing a novel compound formulation as a prophylactic treatment for stress, anxiety and PTSD. Ketamine-based SPC-15 is currently undergoing studies on dosage and delivery methods. These, coupled with published...

Life sciences biotech company Cybin Inc. (NYSE: CYBN) announced its selection of the Generalized Anxiety Disorder (GAD) with or without Major Depressive Disorder (MDD) as the target indication for its proprietary deuterated DMT molecule, CYB004. Anxiety disorders are the most common mental health...

It’s the beginning of 2023 and psychedelics companies are updating the public on their developmental and clinical progress as well as their selected milestones for the year. Cybin’s Programs For MDD And Anxiety Disorders Cybin Inc. (NYSE: CYBN) outlined its near-term goals...

A new scientific publication recently came out in the Biological Psychiatry journal announcing that results of an ongoing Phase 2 study of LSD-assisted therapy for patients suffering from anxiety with or without life-threatening illnesses show encouraging drug effects. The trial was led by the...

Psychedelics company Cybin Inc. (NEO: CYBN) (AMEX: CYBN) announced that the U.S. Patent and Trademark Office has granted U.S. patent 11,242,318 to the company’s investigational deuterated dimethyltryptamine (“DMT”) compound CYB004. The allowed claims include a range of...